<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 59 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page58.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=59">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 59 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 59</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=59"><img src="../thumb/59.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>28 / 2020-04                                                        Central Nervous System - 1.5.3
   trem., dyston., tard. dyskines., dyskines., blurr.vis., conjunctivit., ver-  death, cerebrovasc.accid.& TIA’s, orthostat. hypotens., seiz., head-  Drug interactions: Use with other concom. meds.not system.eval.,
   tigo, dyspn., cough, nas.congest., pharyngolaryng. pain, N&V, diarrh.,   ache, fatig., weight gain, angioed. & other allerg.reacts., decr.neutropil   may antagon.eff.of levodopa & other dopamine agonists, carbamaz-
   constip., abdom. pain, dyspeps., toothache, dry mouth, stomach dis-  &/thrombocyte count, rhinit., water intoxicat.due to polydips./SIADH   epine & other hepat.enzyme induc.may decr.plasma lev., incr. plasma
   comf., gastrit., urin.incontin., rash, eczema, arthralg., back-/extremit.  & body temp.disregulat., incr. plasma prolact.lev.& assoc.manifestat.,   lev.with phenothiaz. / TCA’s/some ß-block./fluoxetine.& paroxet., ci-
   pain, myalg., hyperglycaem., pneum., influenza, LRTI, bronchit., UTI,   psych. disords., somnol., imp.conc., CNS effs., dos. depend. extrapy-  metidine & ranitidine incr.bioavailabil.
   ear infect., sinusit., vir.infect., rhinit., pharyngit., fall, hyper-/hypotens.,   ramid.sympts.incl.trem./rigidity/ hypersalivat./ bradykines./oculogyric
   pyrex., periph. oed., chest pain, fatig., pain, inj.site pain, asthen.,   cris./ akathisia/ ac.dyston.& hypokines., CVA, blurr.vis., reflex tachy-  RISPEVON, (Activo) Trinity [P/S]
   influenza-like illn., malaise, amenorrh., erect. dysfunct., galactorrh.,   card./hypertens., GI disturbs., skin rash, urin.incont., erect.dysfunct.,   Risperidone
   oligomenorrh., breast discomf., ejaculat.disord., agitat., sleep dis-  ejaculat./orgast. dysfunct., priapism, incr.in plasma prolact.result in. or   Indications: Ac.& chron.schizophren.psychos.& relat. psychos.
   ord. Uncommon: Prolong.ECG QT, bundle branch block, bradycard.,   assoc.with galactorrh./gynaecomast./menstr. cycle disturbs.& amen-  where posit.&/or negat.sympts.are promin., affect.sympts.assoc.
   sinus bradycard., palpitat., neutropen., convuls., syncope, postur.diz-  orrh., imp.ment.alertn., hyperglycaem. & exacerbat.of pre-exist.diab.  with schizophren., maint. clinic. improvem.where init.treatm.reponse
   zin., hypoaesthes., paraesthes., lethargy, ear pain, urin. retent., pru-  Special precautions: High.mortalit.report.in elderly dement.pts.  shown, behav.disturbs.in pts.with dement.when aggressiven./ activ.
   rit., acne, dry skin, musc.weakn., neck-/buttock -& musculoskelet.  receiv.furosemide, avoid dehydrat. in pts.receiv.furosemide, monit.  disturbs./psychot.sympts.are promin., conduct & disrupt.behav.dis-
   chest pain, incr./decr. appetite, cystit., gastroenterit., infect., localis.   gluc. control in diab.mellit., diab.mellit.risk fact., high. incid. cerebro-  ords.in childr. 5-12 yrs.with subaveg.intellect.funct./ment. retard.
   infect., inj.site pain, orthostat.hypotens., inj.site indurat., indurat.,   vasc.accid.& TIA’s report.in elderly with dement., Parkinson.dis.as   where destruct.behav.is promin.
   chest discomf., sluggishn., feel. abnorm., hypersens., sex.dysfunct.,   at risk of NMS & incr. antipsychot.med.sensitiv., high.mortalit. re-  (S5) TABS, 43/2.6.5/0039, 0040, 0041, 0042
   gynaecomast., decr. libido, nervousn. Postmarket: Agranulocytos.,   port. in elderly treat.pts., concom.alcoh.& other central. act.meds.,   718226-002: 1 mg, 30, R231,00
   thrombocytopaen., inappropr. antidiuret.hormone secret., diabet.  known CV dis.where grad.dos. titrat. recomm., consid.dos.reduct.  718226-001: 1 mg, 60, R462,00
   ketoacidos., water intox., diab.mellit., hypoglycaem., cholester./ tri-  if hypotens. develops, epilep., post-market.advers.effs.observ. in   718227-002: 2 mg, 30, R495,00
   glycer.incr., cataton.., mania, sleep relat. eat.disord., somnabulism,   neonates expos.dur.last trimest.of pregn., excret. in human breast   718227-001: 2 mg, 60, R990,00
   dygeus., retin.art. occlus.report.with Consta in pres.of intracard. de-  milk, ren.& hepat. impairm., sometimes diffic.to differen.advers.  718228-002: 3 mg, 30, R740,10
   fect predispos.to a right-to-left shunt, intraoperat. floppy iris syndr.  effs. from sympts.of underly.psychos., TD risk incr.with ther. durat.&   718228-001: 3 mg, 60, R1 480,20
   (IFIS), atrial fibrillat., DVT, pulm.embol., sleep apnoea syndr., pancre-  tot.cumulat.dos., prescrib.in manner to minim.TD risk, with S&S of   718229-001: 4 mg, 60, R1,889.62
   atit., paralyt.ileus, jaund., angioedem., alopec., urin.retent., priapism.,   tard.dyskines. consid. discont., discont.all anti-psychot.& not essent.   Dosage: Schizophren: When switch.from other antipsychot. & if
   neonat.drug withdr. syndr., hypotherm., inj.site abscess/-cellullit./-  meds.if NMS.develops, consid.re-introduct. caref. & monit.aft.NMS   medic.appropriate discont.prev. treatm. grad.& if switch.from depot
   cyst/-haematoma/-necros./-ulc., anaphylact.react. with Consta in   recov.as NMS recurr. report., preventat.hypo-oestrog.bone loss ther.  antipsychot. init. Rispevon in place of next sched.inj. Re-eval. need
   pts.prev.tol.oral risperidone  in premenopaus. women with second.amenorrh.of &gt;6 mnths., reg.  for cont.exist.anti-Parkinson meds.period. Dos.above 6 mg/day when
   Warnings and special precautions: Incr. mortality & cerebro-  assess contin.ther., refrain from excess. eat., no caus.assoc.detect.  admin.twice dly.are assoc.with more extra pyramid.sympts and other
   vasc.event risk in elderly with dement., dehydrat., in known CV dis.  with report benign pituit.adenomas.  adv. effs.theref.gen.not recomm.
   grad.titrat. dos. as recomm., consid.dos.reduct.if hypotens. develops,   Drug interactions: Use with other concom. meds. not system.eval.,   Dos.above 10 mg/day have not been shown to be superior in effic.&
   cons.benef./risk in pregn., excret.in breast milk, risk fact.for leuco-  may antagon.eff.of levodopa & other dopamine agonists, carbamaz-  may incr.incid.of S/E & should only be consid.aft.eval.risk vs.benef.
   pen.&/neutropen. incl. pre-exist.low WBC/drug induc.hist.thereof,   epine & other hepat.enzyme induc.may decr.plasma lev., incr. plasma   Add benzodiazep. if addit.sedat.reqd.
   monit. pts.with clinic.signif.neutropen.for fev./ other signs of infect.,   lev.with phenothiaz./TCA’s/some ß-block./ fluoxetine/ paroxetine &   Adults: Indiv. Admin.1-2xdly. Init.2 mg/day.incr. to 4 mg on 2nd
   discont.ther.in case of absol. neutroph. count &lt; 1x 10 /l & foll.WBC   CYP2D6 inhibit., cimetidine & ranitidine incr.bioavail.  day, indiv.furth.if reqd. Usual optim. dos.is 4-8 mg/day. Max.tot.dly.
                         9
   count unt. recov., identify risk fact.for ven.thromboembol. bef. init./dur.  dos: 16 mg/day. Elderly: Init.0,5 mg 2x dly.adjust.in 0,5 mg 2xdly.
   treatm., extrapyramid. sympts.risk fact.for tard.dyskines. developm.,   RISPERLET, (Sanofi Aventis) Janssen-Cilag [P/S]  increm.to 1-2 mg 2x dly.
   cons.discont.ther.if S&S of tard.dyskines.appear, poss.extrapyramid.   Risperidone  Behav.disturbs.in pts.with dement: Init. 0,25 mg 2xdly. Indiv.if
   sympts.with concom.psychostimul., discont.all anti-psychot.if neuro-  Indications: Ac.& chron.schizophren.psychos.& relat. psychos.  necess.in increm.of 0,25 mg 2xdly.not more freq.than every other day.
   lept.malign.syndr.devel., anaphylact. reacts. report.with CONSTA al-  where posit.&/or negat.sympts. are promin., behav.disturbs.in pts.  Optim. dos: 0,5 mg 2xdly.with some benefit.from dos.of up to 1 mg
   though oral risperidone prev.tol., monit.gluc.control of exist. diabet./   with dement. when aggressiven./activ.disturbs./ psychot. sympts. are   2xdly. Once target.dos. reach.consid. once dly.dos. Ongoing eval.&
   hyperglycaem.sympts.in those at risk, continuat.of anti-diabet.treatm.  promin., conduct & disrupt.behav. disords.in childr. 5-12 yrs.with sub-  justificat. of cont. treatm.
   poss.necess. desp. ther.discont., monit.weight gain, card. dysrhythm.   aveg.intellect. funct./ ment. retard.where destruct.behav.is promin.  Conduct & disrupt.behav.disords.in childr.5-12 yrs: &lt;50 kg:
   hist./congen.long QT syndr./concom. meds. known prolong.QT interv.,   (S5) TABS, A40/2.6.5/0727, 0728, 0729  Init.0,01 mg/kg once dly. Indiv. adjust. in increm.of 0,01 mg/kg
   condits.poss. contribut. to core body temp.elev., anti-emet.eff. poss.   711419-001: 0,5 mg, 30, R283,80  once dly.every other day if reqd. Recom.maint.dos: 0,02-0,04 mg /
   mask S&S of cert.meds.overdos./condits.eg. intest. obstruct./Reye’s   711420-001: 1 mg, 30, R490,31  kg once dly. Mean dos: 0,03 mg/kg once dly. Ongoing eval.& jus-
   syndr./brain tumour, seiz. hist./condits.low.seiz.thresh., ren.& hepat.   711421-001: 2 mg, 30, R825,67  tificat.of cont.treatm.
   impairm., sedat.more freq.report.in childr.than adolesc./ adults, IFIS   Dosage: Schizophren: When switch.from other antipsychot. &   Contraindications: Safety & effic.in childr.und.5 yrs. for conduct
   poss.dur.catar.surg.& benef. vs. risk of discont.to be est.prior to surg.,   if medic.appropriate discont.prev. treatm.grad.& if switch.from de-  & other disrupt.behav.disords.not est., Lewy body dement., safety
   elderly, concom. alcoh.& CNS depress., inadvert.inj.of CONSTA in bld.  pot antipsychot. init. Risperlet in place of next inj. Re-eval.need for   in pregn.& lactat. not est., safety & effic.in childr.und.15 yrs.for
   vessel., lact.intol.for Risperdal tabs., re-eval.Risperdal dos.on discont.  cont.exist.anti-Parkinson meds. period. Dos. above 10 mg/day have   schizophren. not est., galact.lintol., Lapp lactose defic., gluc.-ga-
   of carbamazep./ hepat.enzym.induc., do not store CONSTA vial aft.  not been shown to be superior in effic.& may incr. incid.of S/E &   lact.malabsorpt.
   reconstit.as suspens.may settle, eval. effs.bef.act.req.ment.alertn.,   should only be consid.aft. eval.risk vs. benef. Add benzodiazep. if   Side effects: Tard.dyskines.most.in elderly & esp. elderly fem., neu-
   Interactions: Use with other concom.meds.not system. eval., CNS   addit. sedat.reqd.  rolept.malign.syndr., hyperglycaem. assoc.with ketoacidos.& coma/
   depress.with alcoh.& other centr. act.meds., may antagon.eff.of levo-  Adults: Indiv. Admin.1-2xdly. Init. 2 mg/ day.incr. to 4 mg on 2nd   death, cerebrovasc.accid.& TIA’s, orthostat. hypotens., seiz., decr.
   dopa & other dopamine agonists, poss.extrapyramid. sympts. with   day, indiv.furth.if reqd. Usual optim. dos.is 4-8 mg/day. Max.tot.dly.  neutrophil & thrombocyte count, water intoxicat.from polydips.or
   concom.psychostimul., signif. hypotens. with concom.antihypertens.  dos: 16 mg/ day. Elderly: Init.0,5 mg 2x dly.adjust. in 0,5 mg 2xdly.   inappropr. antidiuret. hormone secret., body temp. disregulat., incr.
   treatm., caut. with meds.known to prolong QT interv., carbamazepine   increm.to 1-2 mg 2x dly.  plasma prolact.lev.& manifestat., diabet. mellit./diabet.keto-acidos.
   & other hepat.enzyme induc.may decr. plasma lev., re-eval.dos.with   Behav.disturbs.in pts.with dement: Init. 0,25 mg 2xdly. Indiv.  aggravat., psych. disords., somnol., imp.conc., CNS effs., dos. depend.
   concom strong CYP3A4 &/P-gp inhib.or induc., incr.plasma lev. with   if necess.in increm.of 0,25 mg 2xdly.not more freq.than every oth-  extrapyramid.sympts.incl.trem./rigidity/ hypersalivat./bradykines./
   fluoxetine/paroxet./venlafaxine/CYP2D6 inhibit./phenothiaz./TCA’s/  er day. Optim. dos: 0,5 mg 2xdly.with some benefit. from dos.of   oculogyric cris./ akathisia/ ac.dyston.& hypokines., CVA, blurr. vis.,
   cimetidine/ranitidine & some ß-block., incr.mortality in elderly pts.  upto 1 mg 2xdly. Once target.dos. reach.consid. once dly. dos. Eval.  tachycard., hypertens., chest pain, dyspn., cough, dry mouth, pharyn-
   with dement. and concom.furosemide, sertral& fluvoxamine dos.  cont. treatm. reg.  git., rhinit., sinusit., URTI, GI disturbs., skin rash, urin.incont., polyur.,
   above 100 mg/day elev.conc., caus. relationship betw.in utero ex-  Conduct & disrupt.behav.disords.in childr.5-12 yrs: &lt;50 kg:   erect.-/ejaculat.-/orgasm.dysfunct., priapism, decr.libido, gynaeco-
   pos.& congenit. malformat.not est., C max of valproate incr.  Init.0,01 mg/kg once dly. Indiv. adjust. in increm.of 0,01 mg/kg once   mast., galactorrh., menstr.cycle disturbs.& amenorrh., headache,
                                dly.every other day. Recom.maint.dos: 0,02-0,04 mg/kg once dly.
                                                              weight gain, fatig., angio-oed. & other allerg.reacts., imp.ment.
   RISPERIDONE HEXAL, Sandoz [P/S]  Mean dos: 0,03 mg/kg once dly. Eval. ongoing need reg.  alertn., back pain, arthralg.
   Risperidone                  Contra-indications: Safety & effic.in childr.und. 5 yrs.for con-  Warnings and special precautions: Intraoperat. floppy iris syn-
   Indications: Ac.& chron.schizophren.psychos.& relat.psychos.where   duct & other disrupt.behav.disords. not est., Lewy body dement.,   dr.poss.dur.cataract surg. in pts.treat.with alpha1-adrenerg.antagon.
   posit.&/or negat.sympts.are promin., conduct & disrupt.behav.disords.  pregn.& lactat., safety & effic.in childr.und.15 yrs.for schizophren.   eff. theref.advise surgeon prior to surg., high. mortalit. report.in el-
   in childr. 5-12 yrs.with sub-aveg.intellect.funct./ment. retard.where   not est., galactose intol./lapp lactose defic or gluc.-galact.malab-  derly dement.pts.receiv. concom.furosemide, avoid dehydrat.in pts.
   destruct.behav.is promin.    sopt.as contains lactose      receiv.furosemide, monit.gluc.control in diab. mellit., diab.mellit.risk
   (S5) TABS, 42/2.6.5/0100, A39/2.6.5/0478, 0479, 0480  Side-effects: Tard.dyskines.most.in elderly & esp. elderly fem.,   fact., high.incid. cerebrovasc. accid.& TIA’s report.in elderly with de-
   712252-001: 0,5 mg, 30, R239,37  neurolept.malign.syndr., hyperglycaem.assoc.with ketoacidos.&   ment., Parkinson.dis/dement.with Lewy bod.at risk of NMS & incr.
   710790-001: 1 mg, 30, R409,74  coma/ death, cerebrovasc.accid.& TIA’s, orthostat. hypotens., seiz.,   antipsychot.med.sensitiv., high. mortalit. report.in elderly, concom.
   710791-001: 2 mg, 30, R694,97  headache, weight gain, fatig., angio-oed./skin rash & other allerg.re-  alcoh.& other central. act.meds., known CV dis.where grad.dos.
   710793-001: 3 mg, 30, R1 015,92  acts., decr. neutropil &/thrombocyte count, hyperprolactinaem., inap-  titrat. recomm., consid.dos.reduct.if hypotens. develops, epilep.,
   Dosage: Schizophren: When switch.from other antipsychot.& if   propr.antidiuret. hormone secret., galactorrh./gynaecomast./ menstr.   post-market.advers.effs.observ. in neonates expos.dur.last trimest.
   medic.appropriate discont.prev. treatm.grad.& if switch.from depot   cycle disturbs.& amenorrh., dos.depend. extrapyramid.sympts.incl.  of pregn., excret. in human breast milk, ren.& liv.impairm., some-
   antipsychot. init. Risperidone-Hexal in place of next inj. Dos. above   trem./rigidity/ hypersalivat./ bradykines./oculogyric cris./ akathisia/   times diffic.to differen.advers.effs.from sympts. of underly.psychos.,
   10 mg/day have not been shown to be superior in effic.& may incr.  ac.dyston.& hypokines., CNS effs., blurr.vis., tachycard., hypertens.,   TD risk incr.with ther. durat.& tot.cumulat.dos., prescrib.in manner to
   incid.of S/E. Benzodiazep.may be add.if addit.sedat.is reqd.  GI disturbs., polydips., water intoxicat., psych.disords., erect.-/ejacu-  minim. TD risk, reserve treatm.for pts. obtain. substant. benef., reg.
   Adults: Indiv. Admin.1-2xdly. Init. 2 mg/day.incr. to 4 mg on 2nd   lat.-/orgast.dysfunct., priapism, rhinit., urin. incont., body temp.dis-  assess contin.ther., with S&S of tard.dyskines.consid.discont., dis-
   day, indiv.furth.if reqd. Usual optim.dos.is 4-8 mg/day. Max.tot.dly.  regulat., imp.ment. alertn.  cont.all anti-psychot. & not essent.meds.if neurolept. malign. syndr.
   dos: 16 mg/day. Elderly: Init.0,5 mg 2x dly.adjust.in 0,5 mg 2xdly.  Special precautions: High.mortalit.report.in elderly dement.pts.  develops & instit.treatm., consid. re-introduc. caref.& monit.aft.NMS
   increm.to 1-2 mg 2x dly.     receiv.furosemide, avoid dehydrat.in pts.receiv.furosemide, monit.  recov.as NMS recurr. report., preventat.hypo-oestrog.bone loss ther.
   Conduct & other disrupt.behav.disords.in childr.5-12 yrs:   gluc. control in diab.mellit., diab.mellit.risk fact., Parkinson.dis., some-  in premenopaus.women with second. amenorrh. of &gt;6mnths., refrain
   &lt;50 kg: Init.0,01 mg/kg once dly. Indiv.adjust.in increm.of 0,01 mg/kg   times diffic.to differen. advers. effs.from sympts.of underly.psychos.,   from excess.eat., no caus.assoc.detect.with report benign pituit. ad-
   once dly.every other day. Recom.maint.dos: 0,02-0,04 mg/kg once dly.   concom.alcoh.& other central.act.meds., known CV dis. where grad.  enomas., concom.meds know to prolong QT interv., re-eval.dos.on
   Mean dos: 0,03 mg/kg once dly. Eval.ongoing need reg.  dos.titrat.recomm., consid. dos. reduct.if hypotens.develops, epilep.,   discont.of carbamazepine & other hepat.enzyme induc.
   Contraindications: Safety & effic.in childr.und. 5 yrs. for conduct &   excret. in human breast milk, ren.& liv.impairm., prescrib. in manner   Interactions: Use with other concom.meds.not system.eval., may
   other disrupt.behav.disords.not est., Lewy antibody dement., safety   to minim.TD risk, reg.assess contin.ther., with S&S of tard.dyskines.  antagon.eff.of levodopa & other dopamine agonists, clin.signif.hy-
   in pregn.& lactat. not est., safety & effic.in childr.und.15 yrs. for   consid. discont., discont.all anti-psychot.& not essent. meds. if neu-  potens.with concom. antihypertens., carbamazepine & other hepat.
   schizophren.not est., galactose intol./Lapp lact. defic or gluc.-galact.  rolept.malign.syndr.develops, consid. re-introduct. caref.& monit. aft.  enzyme induc.may decr.plasma lev., incr. plasma lev.with phenothiaz./
   malabsopt.as contains lact.  NMS recov.as NMS recurr.report., preventat.hypo-oestrog. bone loss   TCAs/some ß-block./ fluoxetine.& paroxet./chron.clozapine, cimeti-
   Side effects: Tard.dyskines.most.in elderly & esp.elderly fem., neu-  ther.in premenopaus.women with second. amenorrh. of &gt;6mnths., no   dine & ranitidine incr.bioavailabil., T max of valproate/Li. incr., incr AUC
   rolept.malign.syndr., hyperglycaem. assoc.with ketoacidos.& coma/   caus.assoc.detect. with report benign pituit.adenomas.  & decr.clear.with concom. venlafaxine</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page58.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page54.html">54</a>&nbsp;&nbsp;&nbsp;<a href="page55.html">55</a>&nbsp;&nbsp;&nbsp;<a href="page56.html">56</a>&nbsp;&nbsp;&nbsp;<a href="page57.html">57</a>&nbsp;&nbsp;&nbsp;<a href="page58.html">58</a>&nbsp;&nbsp;&nbsp;<a href="page59.html">59</a>&nbsp;&nbsp;&nbsp;<a href="page60.html">60</a>&nbsp;&nbsp;&nbsp;<a href="page61.html">61</a>&nbsp;&nbsp;&nbsp;<a href="page62.html">62</a>&nbsp;&nbsp;&nbsp;<a href="page63.html">63</a>&nbsp;&nbsp;&nbsp;<a href="page64.html">64</a>
             </td>
             <td width="35%"><a href="page60.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page60.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
